Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function

Area of Science:

• Endocrinology
• Metabolic Diseases
• Mitochondrial Biology

Background:

• Type 2 diabetes mellitus (T2DM) prevalence is rising globally, contributing to significant morbidity and mortality.
• Pathophysiological mechanisms include oxidative stress, inflammation, insulin resistance, and beta-cell dysfunction.
• Emerging evidence highlights mitochondrial dysfunction's critical role in T2DM onset and progression, especially in diabetic complications.

Purpose of the Study:

• To review the role of mitochondrial dysfunction in the pathogenesis of T2DM.
• To explore how antidiabetic therapeutic agents modulate mitochondrial function.
• To investigate potential therapeutic effects of antidiabetic agents on mitochondria, independent of glycemic control.

Main Methods:

• Literature review of studies investigating mitochondrial dysfunction in T2DM.
• Analysis of research on the effects of various antidiabetic medications on mitochondrial pathways.
• Synthesis of evidence linking mitochondrial function to T2DM pathophysiology and treatment.

Main Results:

• Mitochondrial dysfunction is implicated in multiple T2DM-related pathways, including impaired energy metabolism and increased oxidative stress.
• Several antidiabetic agents demonstrate the ability to positively influence mitochondrial function.
• Observed improvements in mitochondrial health by certain drugs may contribute to their therapeutic benefits beyond glucose lowering.

Conclusions:

• Mitochondrial dysfunction is a central factor in T2DM pathogenesis and the development of its complications.
• Targeting mitochondrial pathways represents a promising therapeutic strategy for T2DM.
• The non-glycemic effects of antidiabetic drugs on mitochondria warrant further investigation for comprehensive T2DM management.